Argenx’s $2.2 Billion Bought a Phase 1b With Ten Patients on Placebo
FB102’s entire human efficacy dataset in vitiligo is 42 patients, ten of them on placebo. argenx paid $2.2 billion in cash, with no milestones.
Merger & Acquisitions
Medicover Calls India a Distraction. KKR Just Paid 5.4x Revenue for It.
Medicover is selling India to buy back management focus. KKR is paying 5.4 times revenue for exactly that. Both can be right.
DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead
Every July metric fell except the median and the cash share. Vertex paid a 102% premium for Crinetics and carried a fifth of the month alone.
DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B
DealFlow H1 2026 Review: M&A Rebounds as Upfront Deal Spending Doubles Synopulse · DealFlow · Healthcare & life sciences dealmaking · H1 2026 review M&A came back big, and wrote the cheque in cash M&A value rose 96% to $188 billion in the first half of 2026 and upfront payments jumped 72%, as acquirers paid … Read more
DealFlow: Biopharma Deals This Week June 22–28, 2026
DealFlow Weekly — Wk 26 · 2026 · Synopulse DealFlow WeeklyOn a deep pine background, a faint network of the week’s thirty-five deals fades in while a gold deal line draws across and five gold molecular-ring nodes bloom along it, beside the DealFlow Weekly wordmark and the tagline a weekly readout from Synopulse. SYNOPULSE — … Read more
Lilly’s Quiet $21B Sprint: Seven Deals, One Strategy Hiding in Plain Sight
While the industry debated whether GLP-1 mania had peaked, Eli Lilly closed seven acquisitions in 134 days.
February 2026 Deal Report: Five Signals from $53B in Activity
February 2026 recorded 218 biopharma transactions totalling $53B in disclosed value.
Lilly to buy Ventyx for $1.2B, bolstering oral inflammation pipeline
Lilly acquires Ventyx to expand oral inflammation pipeline.
Lilly in advanced talks to buy Ventyx in a deal topping $1B
Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1B, a move that would add inflammatory bowel disease and neurology assets.
BioMarin to Acquire Amicus for $4.8B in Rare Disease Deal
BioMarin will acquire Amicus Therapeutics for $4.8B in cash, adding Galafold and Pombiliti + Opfolda and accelerating rare-disease revenue growth.